Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program (2022) Dubinsky MC, Magro F, Steinwurz F, Hudesman DP, Kinnucan JA, Ungaro RC, Neurath M, et al. Journal article Impact of Epithelial Cell Shedding on Intestinal Homeostasis (2022) Ngo PA, Neurath M, Lopez Posadas R Journal article, Review article SMYD2 Inhibition Downregulates TMPRSS2 and Decreases SARS-CoV-2 Infection in Human Intestinal and Airway Epithelial Cells (2022) Yu Y, Herrmann A, Thonn V, Cordsmeier A, Neurath M, Enßer A, Becker C Journal article Impact of Cytokine Inhibitor Therapy on the Prevalence, Seroconversion Rate, and Longevity of the Humoral Immune Response Against SARS-CoV-2 in an Unvaccinated Cohort (2022) Simon D, Tascilar K, Kleyer A, Fagni F, Krönke G, Meder C, Dietrich P, et al. Journal article Telomerase deficiency reflects age-associated changes in CD4+T cells (2022) Matthe D, Thoma OM, Sperka T, Neurath M, Waldner M Journal article Scavenging of bacteria or bacterial products by magnetic particles functionalized with a broad-spectrum pathogen recognition receptor motif offers diagnostic and therapeutic applications (2022) Friedrich B, Lyer S, Janko C, Unterweger H, Brox R, Cunningham S, Dutz S, et al. Journal article Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries (2022) Linschoten M, Uijl A, Schut A, Jakob CEM, Romao LR, Bell RM, Mcfarlane E, et al. Journal article Neuroendocrine Tumor Treatments and Follow-up Disease Management: Comparative Perspective (US and Canada vs Global) (2022) Kolarova T, Hollander R, Mcdonnell M, Bouvier C, Pavel ME, Singh H, Howe J, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution